2021-08-18
REL
RCSB
RCSB
RCSB
2021-03-01
2021-03-31
2021-03-31
2021-08-18
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
AI145687
United States
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation
Gobeil S
Acharya P
Gobeil SM
Janowska K
McDowell S
Mansouri K
Parks R
Stalls V
Kopp MF
Manne K
Li D
Wiehe K
Saunders KO
Edwards RJ
Korber B
Haynes BF
Henderson R
Acharya P
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.
Science
US
373
2021
34168071
doi:10.1126/science.abi6226
1095-9203
0038
SCIEAS
Gobeil SM
Janowska K
McDowell S
Mansouri K
Parks R
Stalls V
Kopp MF
Manne K
Saunders K
Edwards RJ
Haynes BF
Henderson RC
Acharya P
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity.
Biorxiv
US
2021
33758838
doi:10.1101/2021.03.11.435037
EMD-23556
associated EM volume
EMD-23555
other EM volume
EMD-23557
other EM volume
EMD-23558
other EM volume
EMD-23559
other EM volume
7lwt
FULLOVERLAP
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7)
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7)
0
1
Severe acute respiratory syndrome coronavirus 2
Homo sapiens
Spike glycoprotein
Severe acute respiratory syndrome coronavirus 2
0.142128172
C-terminal tag: T4 fibritin trimerization motif (GYIPEAPRDGQAYVRKDGEWVLLSTFL) + HRV3C site (LEVLFQ) + His Tag (HHHHHHHH) + Twin Strep tag (WSHPQFEKGGGSGGGGSGGSAWSHPQFEK)
3
Homo sapiens
LEVO
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYHKNNKSWMESEFRVYSSA
NNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLA
LHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPT
ESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIR
GDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGV
EGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQ
QFGRDIDDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF
QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPINFTISVT
TEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFS
QILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTIT
SGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLV
KQLSSNFGAISSVLNDILARLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFC
GKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTHNTFVS
GNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
GKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSLEVLFQGPGHHHHHHHHSAWSHPQFEKGGGSGGGGSGGSAWSH
PQFEK
2-acetamido-2-deoxy-beta-D-glucopyranose
0.000221208
30
NAG
singleParticle
particle
1.5
8.0
ETHANE
FEI TITAN KRIOS
OTHER
BRIGHT FIELD
FIELD EMISSION GUN
300
GATAN K3 (6k x 4k)
52.65
1
PDB 7JMO, 7KDL
3.19
FSC 0.143 CUT-OFF
163471
NOT APPLICABLE
NOT APPLICABLE
7KDL
7JMO
AB INITIO MODEL